Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 4, 2026 · Material agreement · Investor press release · Financial statements
MIRA PHARMACEUTICALS, INC.
19
Material agreement
Jun 4, 2026
| Item 1.01 | Entered a material definitive agreement |
| Item 7.01 | Regulation FD disclosure (investor press release or presentation) |
| Item 9.01 | Financial statements and exhibits |
MIRA PHARMACEUTICALS, INC. filed this to report entering into or terminating a material contract that could affect operations, partnerships, or future hiring.
1 MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1 Agreement Establishes Global Exclusivity Across MIRA’s Core Therapeutic Pipeline and Enhances Strategic Flexibility for Future Licensing and Partnership Opportunities MIAMI, FL / ACCESS Newswire / June 4, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company focused on the development of proprietary therapeutics for neurologic, neuropsychiatric,…
This filing reports Item 1.01 (entered a material definitive agreement). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
MIRA PHARMACEUTICALS, INC. reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
